FlowOx 2.0, developed in co-creation between Norwegian company Otivio AS and Innokas Medical, is a clinically promising, patented and cost-efficient home treatment solution for Peripheral Arterial...
Recent Posts
Headquartered in Helsinki, Finland, MEGIN is the global leader for magnetoencephalography (MEG) technology used for their non-invasive functional brain mapping solution. A long-term collaboration...
With their next-generation innovation, Synoste aims to renew surgical treatment related to bone deformities. Innokas Medical is involved in this mission by being one of Synoste's co-creation partners...
WellO2, innovation developed by the Finnish company WellO2 Oy (formerly known as Hapella Oy), is a breathing exercise device that strengthens and cleanses the lungs. The mission of the company is to...
Norwegian healthtech innovator Augere Medical AS has selected Innokas Medical as their co-creation partner to offer quality and regulatory as well as design and development support to bring their...
The objective of Finnish-based IVD company Aidian is to promote efficient and fluent healthcare by developing and manufacturing reliable, fast and easy to use diagnostic tests for point of care....
Danish company Samplix ApS selected Innokas Medical to co-create the novel Xdrop™ instrument for droplet-based PCR-free enrichment of genomic regions.
The objective of Finnish healthcare technology company Lymphatouch’s negative pressure treatment is to improve patients’ quality of life by reducing pain and tissue swelling. Innokas Medical is...
FlowOx 2.0, developed in co-creation between Norwegian company Otivio AS and Innokas Medical, has now reached a significant milestone as the device has received CE mark and the sales has started. The...
